Imagion Biosystems Ltd. · ASX:IBX
Imagion Biosystems — Investor Presentation (August 2024)
20 slides from Imagion Biosystems's investor presentation, Aug 15, 2024
Slide 1: Company Announcement: Investor presentation
Company Announcement IMAGION BIOSYSTEMS LIMITED ASX: IBX 15 August 2024 Investor presentation MELBOURNE – Imagion Biosystems (ASX:IBX), a company dedicated to improving healthcare through the early detection of cancer, today advises it has released the attached investor presentation which will be pr
Slide 2: A Breakthrough in Molecular MRI Imaging Agents for Cancer Detection
For personal use only MRI Imaging A Breakthrough in Molecular Magnetic Resonance Imaging Agents for Cancer Detection Imagion Biosystems Limited ASX:IBX 1 IBX Investor Deck Copyright August 2024 | ImagionBiosystems.com
Slide 3: Imagion Biosystems Overview
Imagion For personal use only Biosystems Overview Imagion Biosystems ASX:IBX 2 IBX Investor Deck Copyright August 2024 | ImagionBiosystems.com
Slide 4: Imagion Biosystems Overview
Imagion Biosystems Overview A clinical stage biotechnology company developing For personal use only magnetic nanoparticle-based imaging and drug delivery technologies Molecular Imaging Lead Product Targeted nanoparticles have the potential to improve A Phase 1 study for the detection of nodal metast
Slide 5: An Unmet Need in Cancer Diagnosis
An Unmet Need in Cancer Diagnosis For personal use only Screening Imaging Biopsy Conventional blood-based Current imaging To confirm if a lesion is malignant, biopsies tests, like PSA or CA125, methods can be used are taken which may be painful and cause indicate risk of cancer but to identify a “re
Slide 6: Enabling Molecular Imaging
Enabling Molecular Imaging For personal use only Conventional Imaging MagSense®Imaging Images provide anatomical context but are not Molecularly targeted imaging agents produce a specific and can only identify a region of distinct image pattern indicating the presence of a interest. tumor. 5 IBX Inv
Slide 7: How molecular MRI works
MagSense® nanoparticles enable molecular imaging by producing an identifiable change in image contrast when cancer cells are present How molecular For personal use only MRI works • A targeting moiety (e.g. antibody or peptide) directs the nanoparticles to the target tissue to ensure cancer specific
Slide 8: MagSense Molecular Imaging
® MagSense Molecular Imaging For personal use only MagSense® technology aims to transform how medical imaging can detect and diagnose cancer MRI-based Specific Safer Earlier Platform Detection Detection Technology Imaging agents work with Targeted imaging agents Does not require use of Would enable
Slide 9: MagSense Use Cases
® MagSense For personal use only Use Cases 8 IBX Investor Deck Copyright August 2024 | ImagionBiosystems.com
Slide 10: MagSense Use Cases
MagSense® Use Cases For personal use only Detection of Nodal Metastases in Primary Tumor Detection Early Detection of Ovarian Cancer HER2+ Breast Cancer in Prostate Cancer Following primary tumor diagnosis determine if Following primary tumor diagnosis determine if Following elevated PSA blood test,
Slide 11: Clinical Study – IBI010103
Clinical Study – IBI010103 For personal use only Detection of Nodal Metastases in HER2+ Breast Cancer • A Phase 1 Study with 13 HER2+ Breast Cancer patients from 4 sites in Australia. • Imaging agent was safe and well tolerated in all 13 patients with no AE/SAEs reported related to the imaging agent
Slide 12: Improving Radiological Review
Improving Radiological Review For personal use only • Radiological assessment is often Post-Contrast subjective, with significant inter-operator differences in interpretation. • Development of automated software solutions will allow reliable, automated detection for easier, accurate reads. • Using c
Slide 13: Rationale for MRI Imaging Agents
Rationale for MRI Imaging Agents For personal use only Expanding access, Improving outcomes 1. There are >50,000 MRI scanners available globally (5x as many as PET imaging systems). 2. MagSense® imaging agents have long shelf life and can be stored and supplied by the hospital pharmacy without the c
Slide 14: Investor Rationale
For personal use only Investor Rationale 13 IBX Investor Deck Copyright August 2024 | ImagionBiosystems.com
Slide 15: Path to Growth and Value
Path to Growth and Value For personal use only Clinical Development Plan and Key Milestones $3-4B Market Completed 2024 - 2025 Opportunity HER2+ IND Nodal Testing and Breast Phase 1 Phase 2 Phase 3 Surveillance Cancer Dose and Image Protocol Optimization $200M+/yr IND Ovarian Primary Diagnosis and C
Slide 16: Focus on Strategic Partnering
Sources: (1) JAMA Oncology. 2022. Medicare Payment Advisory Commission (MedPAC) and Centers for Medicare and Medicaid Services (CMS). Mordor Intelligence. Global Contrast Media Focus on Strategic Partnering Market For personal use only 1. Use of contrast media is well established across medical imag
Slide 17: Comparable Transactions
Comparable Transactions For personal use only Acquirer Target Value AUD Year Notes Strategic investment. Part of $70M AUD $18M 2024 financing transaction. $35M revenue at time of transaction. $310M 2024 Breast cancer Imuno-oncology agent. Acquired $1.6B 2018 following successful Phase 3. All stock a
Slide 18: Imagion 2.0: Restructured Operations and Leadership
Imagion 2.0 For personal use only Restructured Operations and Leadership Robert Proulx Ward Detwiler Melanie Leydin CA FGIA Brett Mitchell Executive Chairman Chief Business Officer Company Secretary & Non-Executive Non-Executive Director Director Robert is an operationally oriented Experienced early
Slide 19: Imagion 2.0 Investor Summary
Imagion 2.0 For personal use only Investor Summary Key Clinical Milestone Strong Significantly reduced Achieved Pipeline operating costs • Phase 1 study in 13 • MagSense® HER2 being • Eliminated costs of R&D and Manufacturing obligations in HER2+ breast cancer readied for IND application favor of ou
Slide 20: For personal use only
For personal use only info@imagionbio.com | ASX:IBX 19 IBX Investor Deck Copyright August 2024 | ImagionBiosystems.com
Imagion Biosystems — Investor Presentation (August 2024) on 6ix